title: Oxytocin and social cognition in affective and psychotic disorders.
abstract: Impairments in social cognition are now recognized as core illness features in psychotic and affective disorders. Despite the significant disability caused by social cognitive abnormalities, treatments for this symptom dimension are lacking. Here, we describe the evidence demonstrating abnormalities in social cognition in schizophrenia, major depressive disorder, and bipolar disorder, as well as the neurobiology of social cognition including the role of oxytocin. We then review clinical trials of oxytocin administration in psychotic and affective disorders and the impact of this agent on social cognition. To date, several studies have demonstrated that oxytocin may improve social cognition in schizophrenia; too few studies have been conducted in affective disorders to determine the effect of oxytocin on social cognition in these disorders. Future work is needed to clarify which aspects of social cognition may be improved with oxytocin treatment in psychotic and affective disorders.
authors.affiliation: Department of Psychiatry, Icahn School of Medicine at Mount Sinai, Psychiatry Box # 1230 One Gustave L. Levy Place, New York, NY 10029, USA; The Mental Health Patient Care Center and the Mental Illness Research Education and Clinical Center, James J. Peters Veterans Affairs Medical Center, 130 West Kingsbridge Road, Bronx, NY 10468, USA; CIBERSAM, Autonoma University of Madrid, Fundacion Jimenez Diaz Hospital, Spain. Electronic address: mercedes.perez@mssm.edu.
authors.forename: M
authors.initials: M
authors.lastname: Mercedes Perez-Rodriguez
authors.affiliation: Department of Psychiatry, Icahn School of Medicine at Mount Sinai, Psychiatry Box # 1230 One Gustave L. Levy Place, New York, NY 10029, USA.
authors.forename: Katie
authors.initials: K
authors.lastname: Mahon
authors.affiliation: Department of Psychiatry, Icahn School of Medicine at Mount Sinai, Psychiatry Box # 1230 One Gustave L. Levy Place, New York, NY 10029, USA.
authors.forename: Manuela
authors.initials: M
authors.lastname: Russo
authors.affiliation: Department of Psychiatry, Icahn School of Medicine at Mount Sinai, Psychiatry Box # 1230 One Gustave L. Levy Place, New York, NY 10029, USA.
authors.forename: Allison K
authors.initials: AK
authors.lastname: Ungar
authors.affiliation: Department of Psychiatry, Icahn School of Medicine at Mount Sinai, Psychiatry Box # 1230 One Gustave L. Levy Place, New York, NY 10029, USA.
authors.forename: Katherine E
authors.initials: KE
authors.lastname: Burdick
mesh_terms: D002986:Clinical Trials as Topic; D003071:Cognition / Q000187:drug effects*; D006801:Humans; D019964:Mood Disorders / Q000188:drug therapy* / Q000523:psychology; D010121:Oxytocin / Q000008:administration & dosage*; D011618:Psychotic Disorders / Q000188:drug therapy* / Q000523:psychology; D011619:Psychotropic Drugs / Q000008:administration & dosage*; D012938:Social Perception
chemical_list: D011619:Psychotropic Drugs; D010121:Oxytocin
keywords: Bipolar disorder; Major depressive disorder; Oxytocin; Schizophrenia; Social cognition